Protection against malignant conversion in SENCAR mouse skin by all trans retinoic acid: Inhibition of the ras p21-processing enzyme farnesyltransferase and Ha-ras p21 membrane localization

Molecular Carcinogenesis

Volumn 17, Issue 1, 1996, Pages 13-22

  Agarwal, Rajesh ^a,b   Mohan, Rajiv R ^a   Ahmad, Nihal ^a   Mukhtar, Hasan ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Farnesyltransferase; Ras oncogene; Ras p21; Retinoic acid; Tumor progression

Indexed keywords

FARNESYLTRANSFERASE; RETINOIC ACID; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CARCINOMA; ENZYME ACTIVITY; ENZYME INHIBITION; MEMBRANE MARKER; MOUSE; NONHUMAN; ONCOGENE; PAPILLOMA; PRIORITY JOURNAL; SKIN TUMOR; TUMOR PROMOTION;

ALKYL AND ARYL TRANSFERASES; ANIMALS; CARCINOMA; CELL COMPARTMENTATION; CELL MEMBRANE; CELL TRANSFORMATION, NEOPLASTIC; CYTOSOL; DITERPENES; ENZYME INHIBITORS; MICE; PAPILLOMA; PROTO-ONCOGENE PROTEINS P21(RAS); SKIN; SKIN NEOPLASMS; TERPENES; TETRADECANOYLPHORBOL ACETATE; TRANSFERASES; TRETINOIN;

ANIMALIA; MAMMALIA;

EID: 0029999976     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199609)17:1<13::AID-MC3>3.0.CO;2-L     Document Type: Article

References (60)

1. Lippman SM, Meyskens Jr, FL. Results of the use of vitamin A and retinoid in cutaneous malignancies. Pharmacol Ther 40:107-122, 1989.
2. Sporn MB, Newton DL. Chemoprevention of cancer with retinoid. Fed Proc 38:2528-2534, 1979.
3. Lotan R. Effects of vitamin A and its analogs (retinoid) on normal and neoplastic cells. Biochim Biophys Acta 605:33-91, 1980.
4. De Luca LM, Darwiche N, Celli G, et al. Vitamin A in epithelial differentiation and skin carcinogenesis. Nutr Rev 52:545-552, 1994.
5. Smith MA, Parkinson DR, Cheson BD, Friedman MA. Retinoids in cancer therapy. J Clin Oncol 10:839-864, 1992.
6. Sporn MB, Roberts AB. Cervical dysplasia regression induced by all-trans-retinoic acid. J Natl Cancer Inst 86:476-477, 1994.
7. Wattenberg LW, Terada M. Molecular biology of cancer: Implications for prevention and therapy. Third Joint Meeting of the American Association for Cancer Research and the Japanese Cancer Association. Cancer Res 55:5472-5481, 1995.
8. Kraemer KH, DiGiovanna JJ, Moshell AN, Tarone RE, Peck GL. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 318:1633-1637, 1988.
9. DiGiovanna JJ, Zech LA, Ruddel ME, Gantt G, Peck GL. Etretinate. Arch Dermatol 125:246-251, 1989
10. Futoryan T, Gilchrest BA. Retinoids and the skin. Nutr Rev 52:299-310, 1994.
11. Chen L-C, De Luca LM. Retinoid effects on skin cancer. In: Mukhtar H (ed), Skin Cancer: Mechanism and Human Relevance. CRC Press, Boca Raton, FL, 1994, pp. 401-424.
12. Athar M, Agarwal R, Wang ZY, Lloyd JR, Bickers DR, Mukhtar H. All trans 'etinoic acid protects against free radical generating compounds-mediated conversion of chemically and ultraviolet B radiation-induced skin papillomas to carcinomas. Carcinogenesis 12:2325-2329, 1991.
13. De Luca LM, Sly L, Jones CS, Chen L-C. Effects of dietary retinoic acid on skin papilloma and carcinoma formation in female SENCAR mice. Carcinogenesis 14:539-542, 1993.
14. Chen L-C, Sly L, De Luca LM. High dietary retinoic acid prevents malignant conversion of skin papillomas induced by a two-stage carcinogenesis protocol in female SENCAR mice. Carcinogenesis 15:2383-2386, 1994.
15. Chen L-C, Tarone R, Huynh M, De Luca LM. High dietary retinoic acid inhibits tumor promotion and malignant conversion in a two-stage skin carcinogenesis protocol using 7, 12-dimethylbenz[a]anthracene as the initiator and mezerein as the tumor promoter in female SENCAR mice. Cancer Lett 95:113-118, 1995.
16. Mohan RR, Katiyar SK, Khan SG, Zaim MT, Mukhtar H, Agarwal R. Protective effect of all trans retinoic acid against tumor promotion and progression in low- and high-risk protocols of mouse skin chemical carcinogenesis. Int J Oncology 8:1079-1088, 1996.
17. DiGiovanni J. Multistage carcinogenesis in mouse skin. Pharmacol Ther 54:63-128, 1992.
18. Brown K, Buchmann A, Balmain A. Carcinogen-induced mutations in the mouse c-Ha-ras gene provide evidence of multiple pathways for tumor progression. Proc Natl Acad Sci USA 87:538-542, 1990.
19. Bowden GT, Finch J, Domann F, Krieg P. Molecular mechanisms involved in skin tumor initiation, promotion, and progression. In: Mukhtar H (ed), Skin Cancer: Mechanism and Human Relevance, CRC Press, Boca Raton, FL, 1994, pp. 99-111.
20. Bremner R, Kemp CJ, Balmain A. Induction of different genetic changes by different classes of chemical carcinogens during progression of mouse skin tumors. Mol Carcinog 11:90-97, 1994.
21. Pelling JC, Ernst SM, Strawhecker JM, Johnson JA, Nairn RS, Slaga TJ. Elevated expression of Ha-ras is an early event in two-stage skin carcinogenesis in SENCAR mice. Carcinogenesis 7:1599-1602, 1986.
22. Pelling JC, Fischer SM, Neades R, Strawhecker J, Schweickert L. Elevated expression and point mutation of the Ha-ras proto-on- cogene in mouse skin tumors promoted by benzoyl peroxide and other promoting agents. Carcinogenesis 8:1481-1484, 1987.
23. Gibbs JB, Oliff A, Kohl NE. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 77:175-178, 1994.
24. ras activity. Trends Gene 7:346-351, 1991.
25. Der CJ, Cox AD. Isoprenoid modification and plasma membrane association: Critical factors for ras oncogenicity. Cancer Cells 3:331-340, 1991.
26. Agarwal R, Khan SG, Athar M, Zaidi SIA, Bickers DR, Mukhtar H. Ras protein p21 processing enzyme farnesyltransferase in chemical carcinogen-induced murine skin tumors. Mol Carcinog 8:290-298, 1993.
27. Khan SG, Bickers DR, Mukhtar H, Agarwal R. Ras p21 farnesylation in ultraviolet B radiation-induced tumors in the skin of SKH-1 hairless mice. J Invest Dermatol 102:754-758, 1994.
28. Khan SG, Saxena R, Bickers DR, Mukhtar H, Agarwal R. Inhibition of ras p21 membrane localization and modulation of protein kinase C isozyme expression during regression of chemical carcinogen-induced murine skin tumors by lovastatin. Mol Carcinog 12:205-212, 1995.
29. Agarwal R, Khan SG, Mukhtar H. Ras p21 post-translational processing: An overview and studies in skin cancer. In: Mukhtar H (ed). Skin Cancer: Mechanism and Human Relevance, CRC Press, Boca Raton, FL, 1994, pp. 293-304.
30. Hennings H, Shores R, Mitchell P, Spangler EF, Yuspa SH. Induction of papillomas with a high probability of conversion to malignancy. Carcinogenesis 6:1607-1610, 1985.
31. James GL, Brown MS, Cobb MH, Goldstein JL. Benzodiazepine peptodomimetic BZA-5B interrupts the MAP kinase activation pathway in H-ras-transformed Rat-1 cells, but not in untransformed cells. J Biol Chem 269:27705-27714, 1994.
32. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254, 1976.
33. Khan SG, Mukhtar H, Agarwal R. A rapid and convenient filter-binding assay for ras p21 processing enzyme farnesyltransferase. J Biochem Biophys Methods 30:133-144, 1995.
34. 4. Nature 227:680-685, 1970.
35. Towbin H, Staehlin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets. Proc Natl Acad Sci USA 76:4350-4354, 1979.
36. Barbacid M Ras genes. Annu Rev Biochem 56:779-827, 1987.
37. Bos JL. Ras oncogenes in human cancer: A review. Cancer Res 49:4682-4689, 1989.
38. Bishop JM. Molecular themes in oncogenesis. Cell 64:235-248, 1991.
39. Bos JL, Fearon ER, Hamilton SR, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 327:293-297, 1987.
40. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53:549-554, 1988.
41. Balmain A, Brown K. Oncogene activation in chemical Carcinogenesis. Adv Cancer Res 51:147-182, 1988.
42. Miyamoto S, Sukumar S, Guzman RC, Osborn RC, Nandi S. Transforming c-Ki-ras mutation is a preneoplastic event in mouse mammary carcinogenesis induced in vitro by N-methyl-N-nitrosourea. Mol Cell Biol 10:1593-1599, 1990.
43. Feig LA. Strategies for suppressing the function of oncogenic ras protein in tumors. J Natl Cancer Inst 85:1266-1268, 1993.
44. Schaber MD, O'Hara MB, Garsky VM, et al. Polyisoprenylation of ras in vitro by a farnesyl-protein transferase. J Biol Chem 265:14701-14704, 1990.
45. Willumsen BM, Christensen A, Hubbert ML, Papageorge AG, Lowy DR. The p21 ras C-terminus is required for transformation and membrane association. Nature 310:583-586, 1984.
46. ras membrane association by dehydroepiandrosterone in human colonic adenocarcinoma cells. Cancer Res 51:6563-6567, 1991.
47. Crowell PL, Chang RR, Ren Z, Elson CE, Gould MN. Selective inhibition of isoprenylation of 21-26-kDa proteins by the anticarcinogen d-limonene and its metabolites. J Biol Chem 266:17679-17685, 1991.
48. Hara M, Akasaka K, Akinaga S, et al. Identification of ras farnesyltransferase inhibitors by microbial screening. Proc Natl Acad Sci USA 90:2281-2285, 1993.
49. Gibbs JB, Pompliano DL, Mosser SD, et al. Selective inhibition of farnesyl-protein transferase blocks ras processing in vivo. J Biol Chem 268:7617-7620, 1993.
50. Kohl NE, Mosser SD, deSolms SJ, et al. Selective inhibition of rasdependent transformation by a farnesyltransferase inhibitor. Science 260:1934-1937, 1993.
51. James GL, Goldstein JL, Brown MS, et al. Benzodiazepine peptidomimetics: Potent inhibitors of ras farnesylation in animal cells. Science 260:1937-1942, 1993.
52. Kohl NE, Wilson FR, Mosser SD, et al. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci USA 91:9141-9145, 1994.
53. 2X peptidomimetics. J Biol Chem 268:20695-20698, 1993.
54. ras farnesyltransferase. J Biol Chem 269:12410-12413, 1994.
55. Manne V, Yan N, Carboni JM, et al. Bisubstrate inhibitors of farnesyltransferase: A novel class of specific inhibitors of ras transformed cells. Oncogene 10:1763-1779, 1995.
56. Singh J, Reddy BS. Effect of chemopreventive agents on posttranslational plasma-membrane association of ras-p21 during chemoprevention of azoxymethane-induced colon carcinogenesis. Int J Oncol 6:301-306, 1995.
57. Lancillotti F, Darwiche N, Celli G, De Luca LM. Retinoid status and the control of keratin expression and adhesion during the histogenesis of squamous metaplasia of tracheal epithelium. Cancer Res 52:6144-6152, 1992.
58. Lotan R, Dawson MI, Zou C-C, Jong L, Lotan D, Zou C-P. Enhanced efficacy of combination of retinoic acid- and retinoid X receptor-selective retinoids and α-interferon in inhibition of cervical carcinoma cell proliferation. Cancer Res 55:232-236, 1995.
59. Widschwendter M, Daxenbichler G, Dapunt O, Marth C. Effects of retinoic acid and γ-interferon on expression of retinoic acid receptor and cellular retinoic acid-binding protein in breast cancer cells. Cancer Res 55:2135-2139, 1995.
60. Lotan R. Retinoids and apoptosis: Implications for cancer chemoprevention and therapy. J Natl Cancer Inst 87:1655-1657, 1995.